A bipartisan group of attorneys including Maryland AG Doug Gansler is urging the FDA to reconsider a recent decision to approve a high-dose narcotic painkiller. AG Doug Gansler says that the FDA went against the recommendation of its advisory panel in approving Zohydro ER in October. The panel voted 11 to 2 against approval because the drug has a high potential for misuse and its lack of abuse-deterrent formulation. Just before approving Zohydro ER, the FDA recommended reclassifying all hydrocodone products to Schedule II controlled substances because of their abuse potential. In a letter to the FDA the Attorneys General said they don’t want to see another vicious cycle of overzealous pharmaceutical sales, doctors over-prescribing the drug and patients tampering with it – resulting in a nationwide prescription drug epidemic that claims thousands of lives.
Return to: WGMD Local News Blog